Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
By K. Ang, Q. Zhang, D. Rosenthal, P. Nguyen-Tan, E. Sherman, R. Weber, J. Galvin, J. Bonner, J. Harris, A. El-Naggar and 10 more. Journal of Clinical Oncology, 2014
731 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/6f4632ffe2ec3438826a5fd8071a43ffcb2c8589
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
In Surgery
Citations in the corpus
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. (2016, background): “In contrast, the addition of cetuximab to cisplatin with radiotherapy revealed no improvement over cisplatin with radiotherapy alone in a phase 3 trial (RTOG 0522).(36) The acute toxicity was worse with cetuximab, cisplatin, and radiotherapy.”
- An update on larynx cancer (2017, background): “Finally, there is no role for adding cetuximab to cisplatin in concurrent therapy, because the results of RTOG 0522 demonstrated no efficacy advantage to this combination approach, but the cetuximab and cisplatin arm had a higher rate of toxicity and more dose interruptions than the cisplatin alone ”
- Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis (2017, background): “, epidermal growth factor inhibitors) amplify OM [4], and may cause dermatitis and resulting in extension to sites beyond the high- dose RT fields.”